Skip to main content
Nora Naumann-Bartsch on Muck Rack

Nora Naumann-Bartsch

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nora

Contact Nora, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases - Nature Medicine

|
By Marco Becilli, Markus Metzler, Claudia Bracaglia, Rebecca Nicolai, Francesca Del Bufalo, Nora Naumann-Bartsch, Pietro Merli, Aurelio Secinaro, Biagio De Angelis, Simon Völkl, Fabian Muller, Andreas Mackensen, Georg Schett, Fabrizio De Benedetti
| Nature Verified
Abstract Chimeric antigen receptor (CAR) T cell therapy was recently proposed as a treatment for adults with B-cell-mediated autoimmune diseases (ADs) refractory to conventional immunomodulatory therapy.
Open in Who Shared Issue with article?

Free-breathing phase-resolved functional lung (PREFUL) low-field magnetic resonance imaging (LF-MRI) of pulmonary dysfunction after surviving childhood cancer | Communications Medicine

|
By Maximilian Hinsen, Eva-Maria Wild, Nadine Bayerl, Rafael Heiss, Armin M. Nagel, Nora Naumann-Bartsch, Adrian P. Regensburger, Ferdinand Knieling, Alexander Dierl
| Nature Verified
Abstract Childhood cancer survivors have a high risk of chronic multi-organ disease that does not plateau over time. To date, there is a lack of sensitive diagnostic techniques that allow early detection of tissue damage before clinical symptoms occur, particularly regarding pulmonary function.
Open in Who Shared Issue with article?

Detection of signature double‐negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function

|
By Nina Eisenhauer, Maurizio Miano, Jörg Leyh, Nora Naumann-Bartsch
| Wiley Online Library Verified
To the Editor: The autoimmune lymphoproliferative syndrome (ALPS) is caused by defects in the FAS-dependent apoptosis leading to chronic lymphoproliferation, autoimmunity, chronic multilineage cytopenia, an increased risk for developing B cell lymphomas, and a characteristic accumulation of CD4/CD8-negative, T-cell receptor (TCR), αβ-positive T-cells (double-negative, DNT-cells).1, 2 The heterogeneous clinical phenotype of ALPS patients and overlap with similar diseases like CTLA-4 and LRBA...
Open in Who Shared Issue with article?
See all 3 articles